Evaluación de la terapia con anticuerpos monoclonares en pacientes con Eslerosis Múltiple.
Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central nervous system, whose management has significantly evolved with the use of monoclonal antibodies (mAbs). It is estimated to be one of the leading causes of non traumatic neurological disability in young adults...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| التنسيق: | bachelorThesis |
| اللغة: | spa |
| منشور في: |
2025
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://dspace.unach.edu.ec/handle/51000/15634 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
إضافة وسم | الملخص: | Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central nervous system, whose management has significantly evolved with the use of monoclonal antibodies (mAbs). It is estimated to be one of the leading causes of non traumatic neurological disability in young adults. An updated bibliographic review was conducted using various search engines, from which information was obtained from relevant scientific databases. Keywords such as multiple sclerosis, monoclonal antibodies, natalizumab, ocrelizumab, alemtuzumab, ofatumumab, safety profile, and efficacy were used. A total of 130 articles were collected, of which 70 met the selection criteria. Each mAb acts on distinct immunological targets (such as integrin α4, CD52, and CD20), modulating autoimmune activity in a specific manner. Regarding efficacy, all demonstrated significant reductions in relapses, disability progression, and lesion activity on MRI, with ocrelizumab being the only one approved for primary progressive MS. Regarding safety, relevant risks were identified, such as progressive multifocal leukoencephalopathy (PML) with natalizumab and secondary autoimmunity with alemtuzumab, while ocrelizumab and ofatumumab showed more tolerable profiles, although they are not exempt from precautions. |
|---|